Targeting LASP1, eIF4A1, eIF4B and CXC4 with modulators and combinations thereof for cancer therapy
AssigneeThe University of Toledo
InventorsDayanidhi Raman, Cory M. Howard, John Nemunaitis, Francis Charles Brunicardi, Shi-He Liu, Amit K. Tiwari
Life of this patent
Estimating the term…
Abstract
Described herein are compositions, formulations, and methods useful for sensitizing cancer cells to chemotherapeutic agents, for inhibiting expression or translation of oncogenic proteins, for inhibiting eIF4A, for inhibiting c-MYC, for reducing sternness of breast cancer cells, for treating breast cancer, for overcoming drug resistance of drug-resistant cancer cells, and for reducing tumor cell viability, involving one or more inhibitors of eIF4A, LASP1, CXCR4, CXCL8, CXCL12, ROCK1, BIRC5, MDM2, CCND1, and c-MYC.
Claims2
A method for reducing breast cancer stemness, the method comprising:
- administering an effective amount of a eIF4A inhibitor to breast cancer stem cells to reduce stemness in the breast cancer cells, wherein the eIF4A inhibitor is a site-directed eIF4A inhibitor;
- wherein the method further comprises administering a survivin inhibitor to the breast cancer stem cells in combination with the eIF4A inhibitor, and wherein the eIF4A inhibitor comprises rocaglamide A and the survivin inhibitor comprises LQZ-7F.
Dependencies are inferred from the claim text.